The advent of immunotherapy has necessitated syngeneic mouse tumor models with desirable growth kinetics and response to immunomodulatory agents to furthe

The steady growth, and interest in immunotherapy has required continual development and optimization of syngeneic mouse tumor models with desirable grow

In preclinical research, small animal in vivo imaging plays an essential role in visualizing physiological processes, progression of disease and development of therapies.

We previously reported a median survival of 35-40 days in the orthotopic ID8 model accompanied by the development of peritoneal ascites.

The number of deaths caused by lung cancer peaked in 2005 at 159,292 and has been gradually declining ever since.^[1] However, the five-year lung cancer survival rate is only around 20% and is considerably lower than other cancers.

To produce Kymriah? or Yescarta?, a patient?s T cells are engineered to express Chimeric Antigen Receptors (CARs) specific for the CD19 B lymphocyte molecule (1).

Treatment options for CRC are highly dependent on the stage of disease, but many patients receive cocktails of chemotherapies and in some cases radiation treatment along with chemotherapy. A number of preclinical xenograft models exist that allow pharmaceutical and biotech companies to investigate new treatment approaches for CRC.

Ovarian cancer is an unmet medical need and particularly lethal because it is often detected only when disease is quite advanced. In 2017, approximately 22,440 women will be diagnosed with ovarian cancer in the United States, and approximately 14,080 deaths will occur.

Preclinically there are few options to test effects of clinically relevant radiation therapy approaches. Labcorp has a Small Animal Radiation Research Platform (SARRP; Xstrahl) in house and can provide a solution to this currently unmet preclinical need.

In the Western population, hepatitis C, alcoholic cirrhosis, and non-alcoholic steatohepatitis (NASH) are the main underlying causes.